Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312681 | 0.92 | EPHB4 (0.37) | HRH4MAPK14DYRK1BKDR | |
| SCHEMBL6417723 | 0.86 | CFD (0.34) | CFDHRH4SYKMAPK14DYRK1B | |
| SCHEMBL5914384 | 0.83 | CFD (0.41) | CFDHRH4SYKMAPK14DYRK1B | |
| SCHEMBL5914205 | 0.82 | CFD (0.39) | CFDHRH4SYKMAPK14DYRK1B | |
| SCHEMBL5913846 | 0.81 | HRH4 (0.38) | CFDHRH4SYKMAPK14DYRK1B | |
| SCHEMBL5913862 | 0.81 | CFD (0.39) | CFDSYKMAPK14KDRMAPK13 | |
| SCHEMBL5315338 | 0.78 | EPHB4 (0.38) | MAPK14DYRK1BKDR | |
| SCHEMBL5310133 | 0.78 | EPHB4 (0.38) | MAPK14DYRK1BKDR | |
| SCHEMBL5914043 | 0.76 | CFD (0.38) | CFDMAPK14DYRK1BKDR | |
| SCHEMBL5914049 | 0.76 | CFD (0.38) | CFDMAPK14DYRK1BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765825-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004702-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1765825-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004702-A1 | CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | CFD 4149/4885HRH4 29/4885SYK 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.